Objective To explore the efficacy of carlizumab and targeted drugs in patients with drug-resistant ad-vanced liver cancer.Methods 80 cases of drug-resistant advanced liver cancer patients admitted to the Department of Oncology of Mengchao Hepatobiliary Hospital of Fujian Medical University from May 2022 to May 2023 were ran-domly analyzed.They were divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with a single targeted drug,and the observation group was treated with targeted drug combined with camrelizumab.Comparisons were made in terms of clinical efficacy,laboratory in-dexes and incidence of adverse reactions between the two groups.Results The objective remission rate of the observa-tion group was 47.50%,which was higher than 25.00%of the control group,and the difference was statistically signifi-cant(χ2=4.381,P<0.05).The disease control rate of 77.50%in the observation group,which was was higher than 52.50%in the control group,and the difference was statistically significant(χ2=5.494,P<0.05).Tumor markers and platelets in the observation group were lower than those in the control group after treatment,and the difference was sta-tistically significant(all P<0.05).There was no statistically significant difference between the two groups in terms of adverse reactions(P>0.05).Conclusion For patients with drug-resistant advanced liver cancer,combined with cam-relizumab on the basis of targeted drug therapy can improve the effect of disease control,reduce the level of tumor markers,and the adverse reactions did not grow significantly,with good tolerability.
维普
万方数据